Skip to main content
Press release August 10, 2026

Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

Ceribell, Inc. (CBLL)

Neurology Review Software Enhancements Included as Part of Industry-Leading Ceribell Point-of-Care Brain Monitoring System SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the
View original release